Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-24-043916
Filing Date
2024-11-07
Accepted
2024-11-07 07:56:11
Documents
64
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 907477
2 ex31-1.htm EX-31.1 21632
3 ex31-2.htm EX-31.2 21045
4 ex32-1.htm EX-32.1 8079
5 ex32-2.htm EX-32.2 8509
  Complete submission text file 0001493152-24-043916.txt   4457710

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE cing-20240930.xsd EX-101.SCH 38543
7 XBRL CALCULATION FILE cing-20240930_cal.xml EX-101.CAL 47554
8 XBRL DEFINITION FILE cing-20240930_def.xml EX-101.DEF 143801
9 XBRL LABEL FILE cing-20240930_lab.xml EX-101.LAB 320605
10 XBRL PRESENTATION FILE cing-20240930_pre.xml EX-101.PRE 247134
67 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 574314
Mailing Address 1901 W. 47TH PLACE KANSAS CITY KS 66205
Business Address 1901 W. 47TH PLACE KANSAS CITY KS 66205 (913) 942-2300
Cingulate Inc. (Filer) CIK: 0001862150 (see all company filings)

IRS No.: 863825535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40874 | Film No.: 241433256
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)